Literature DB >> 23396049

Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.

Steven J Van Laere1, Naoto T Ueno, Pascal Finetti, Peter Vermeulen, Anthony Lucci, Fredika M Robertson, Melike Marsan, Takayuki Iwamoto, Savitri Krishnamurthy, Hiroko Masuda, Peter van Dam, Wendy A Woodward, Patrice Viens, Massimo Cristofanilli, Daniel Birnbaum, Luc Dirix, James M Reuben, François Bertucci.   

Abstract

BACKGROUND: Inflammatory breast cancer (IBC) is a poorly characterized form of breast cancer. So far, the results of expression profiling in IBC are inconclusive due to various reasons including limited sample size. Here, we present the integration of three Affymetrix expression datasets collected through the World IBC Consortium allowing us to interrogate the molecular profile of IBC using the largest series of IBC samples ever reported. EXPERIMENTAL
DESIGN: Affymetrix profiles (HGU133-series) from 137 patients with IBC and 252 patients with non-IBC (nIBC) were analyzed using unsupervised and supervised techniques. Samples were classified according to the molecular subtypes using the PAM50-algorithm. Regression models were used to delineate IBC-specific and molecular subtype-independent changes in gene expression, pathway, and transcription factor activation.
RESULTS: Four robust IBC-sample clusters were identified, associated with the different molecular subtypes (P<0.001), all of which were identified in IBC with a similar prevalence as in nIBC, except for the luminal A subtype (19% vs. 42%; P<0.001) and the HER2-enriched subtype (22% vs. 9%; P<0.001). Supervised analysis identified and validated an IBC-specific, molecular subtype-independent 79-gene signature, which held independent prognostic value in a series of 871 nIBCs. Functional analysis revealed attenuated TGF-β signaling in IBC.
CONCLUSION: We show that IBC is transcriptionally heterogeneous and that all molecular subtypes described in nIBC are detectable in IBC, albeit with a different frequency. The molecular profile of IBC, bearing molecular traits of aggressive breast tumor biology, shows attenuation of TGF-β signaling, potentially explaining the metastatic potential of IBC tumor cells in an unexpected manner. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23396049      PMCID: PMC6156084          DOI: 10.1158/1078-0432.CCR-12-2549

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

1.  Persistent E-cadherin expression in inflammatory breast cancer.

Authors:  C G Kleer; K L van Golen; T Braun; S D Merajver
Journal:  Mod Pathol       Date:  2001-05       Impact factor: 7.842

2.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

3.  A pathway-based classification of human breast cancer.

Authors:  Michael L Gatza; Joseph E Lucas; William T Barry; Jong Wook Kim; Quanli Wang; Matthew D Crawford; Michael B Datto; Michael Kelley; Bernard Mathey-Prevot; Anil Potti; Joseph R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-24       Impact factor: 11.205

4.  PhosphoMARCKS drives motility of mouse melanoma cells.

Authors:  Xiangyu Chen; Susan A Rotenberg
Journal:  Cell Signal       Date:  2010-03-06       Impact factor: 4.315

5.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.

Authors:  François Bertucci; Pascal Finetti; Jacques Rougemont; Emmanuelle Charafe-Jauffret; Nathalie Cervera; Carole Tarpin; Catherine Nguyen; Luc Xerri; Rémi Houlgatte; Jocelyne Jacquemier; Patrice Viens; Daniel Birnbaum
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

6.  Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.

Authors:  Steven J Van Laere; Gert G Van den Eynden; Ilse Van der Auwera; Melanie Vandenberghe; Peter van Dam; Eric A Van Marck; Kenneth L van Golen; Peter B Vermeulen; Luc Y Dirix
Journal:  Breast Cancer Res Treat       Date:  2005-10-27       Impact factor: 4.872

7.  A stromal gene signature associated with inflammatory breast cancer.

Authors:  Brenda J Boersma; Mark Reimers; Ming Yi; Joseph A Ludwig; Brian T Luke; Robert M Stephens; Harry G Yfantis; Dong H Lee; John N Weinstein; Stefan Ambs
Journal:  Int J Cancer       Date:  2008-03-15       Impact factor: 7.396

8.  Array-based DNA methylation profiling for breast cancer subtype discrimination.

Authors:  Ilse Van der Auwera; Wayne Yu; Liping Suo; Leander Van Neste; Peter van Dam; Eric A Van Marck; Patrick Pauwels; Peter B Vermeulen; Luc Y Dirix; Steven J Van Laere
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

Review 9.  Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis.

Authors:  Josef Gotzmann; Mario Mikula; Andreas Eger; Rolf Schulte-Hermann; Roland Foisner; Hartmut Beug; Wolfgang Mikulits
Journal:  Mutat Res       Date:  2004-01       Impact factor: 2.433

10.  NF-kappa B genes have a major role in inflammatory breast cancer.

Authors:  Florence Lerebours; Sophie Vacher; Catherine Andrieu; Marc Espie; Michel Marty; Rosette Lidereau; Ivan Bieche
Journal:  BMC Cancer       Date:  2008-02-04       Impact factor: 4.430

View more
  63 in total

Review 1.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

2.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

3.  Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells.

Authors:  Scott J Sauer; Michael Tarpley; Imran Shah; Akshay V Save; H Kim Lyerly; Steven R Patierno; Kevin P Williams; Gayathri R Devi
Journal:  Carcinogenesis       Date:  2017-03-01       Impact factor: 4.944

Review 4.  Inflammatory Breast Cancer: a Separate Entity.

Authors:  Jennifer M Rosenbluth; Beth A Overmoyer
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

5.  Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Authors:  Jennifer L Allensworth; Myron K Evans; François Bertucci; Amy J Aldrich; Richard A Festa; Pascal Finetti; Naoto T Ueno; Rachid Safi; Donald P McDonnell; Dennis J Thiele; Steven Van Laere; Gayathri R Devi
Journal:  Mol Oncol       Date:  2015-02-21       Impact factor: 6.603

6.  Risk factors for inflammatory breast cancer and other invasive breast cancers.

Authors:  Catherine Schairer; Yan Li; Peter Frawley; Barry I Graubard; Robert D Wellman; Diana S M Buist; Karla Kerlikowske; Tracy L Onega; William F Anderson; Diana L Miglioretti
Journal:  J Natl Cancer Inst       Date:  2013-09-18       Impact factor: 13.506

7.  Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.

Authors:  F Bertucci; N T Ueno; P Finetti; P Vermeulen; A Lucci; F M Robertson; M Marsan; T Iwamoto; S Krishnamurthy; H Masuda; P Van Dam; W A Woodward; M Cristofanilli; J M Reuben; L Dirix; P Viens; W F Symmans; D Birnbaum; S J Van Laere
Journal:  Ann Oncol       Date:  2013-12-02       Impact factor: 32.976

8.  Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.

Authors:  Komal Jhaveri; Eleonora Teplinsky; Deborah Silvera; Amanda Valeta-Magara; Rezina Arju; Shah Giashuddin; Yasmeen Sarfraz; Melissa Alexander; Farbod Darvishian; Paul H Levine; Salman Hashmi; Ladan Zolfaghari; Heather J Hoffman; Baljit Singh; Judith D Goldberg; Tsivia Hochman; Silvia Formenti; Francisco J Esteva; Meena S Moran; Robert J Schneider
Journal:  Clin Breast Cancer       Date:  2015-12-01       Impact factor: 3.225

9.  Current Surgical Management of Inflammatory Breast Cancer.

Authors:  Taiwo Adesoye; Anthony Lucci
Journal:  Ann Surg Oncol       Date:  2021-08-03       Impact factor: 5.344

10.  Epidemiological risk factors associated with inflammatory breast cancer subtypes.

Authors:  Rachel L Atkinson; Randa El-Zein; Vicente Valero; Anthony Lucci; Therese B Bevers; Tamer Fouad; Weiqin Liao; Naoto T Ueno; Wendy A Woodward; Abenaa M Brewster
Journal:  Cancer Causes Control       Date:  2016-01-21       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.